Synapse

← Gordon B. Mills

Papers by Gordon B. Mills

Page 6 · newest first

  1. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of ResponsivenessMolecular Cancer Therapeutics · 2019
  2. Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic AlterationsNeoplasia · 2019
  3. Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesisNature Communications · 2018
  4. Implementing a comprehensive translational oncology platform: from molecular testing to actionabilityJournal of Translational Medicine · 2018
  5. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAnessCancer Research · 2018
  6. PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial CarcinomaClinical Cancer Research · 2018
  7. Confocal Fluorescence Microscopy Platform Suitable for Rapid Evaluation of Small Fragments of Tissue in Surgical Pathology PracticeArchives of Pathology & Laboratory Medicine · 2018
  8. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapiesNature Communications · 2018
  9. The chromatin accessibility landscape of primary human cancersScience · 2018
  10. Personalized Integrated Network Modeling of the Cancer Proteome AtlasScientific Reports · 2018
  11. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in CancerCell Reports · 2018
  12. Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity2018
  13. Modulation of the Hippo pathway and organ growth by RNA processing proteinsProceedings of the National Academy of Sciences · 2018
  14. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β SuperfamilyCell Systems · 2018
  15. Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recoverySHILAP Revista de lepidopterología · 2018
  16. RNA editing derived epitopes function as cancer antigens to elicit immune responsesSHILAP Revista de lepidopterología · 2018
  17. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsCancer Cell · 2018
  18. Comprehensive Characterization of Cancer Driver Genes and MutationsCell · 2018
  19. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsPLoS ONE · 2018
  20. AKT isoform-specific expression and activation across cancer lineagesBMC Cancer · 2018
  21. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancerNature Communications · 2018
  22. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like CellsClinical Cancer Research · 2018
  23. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell CarcinomaCell Reports · 2018
  24. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancerNature Communications · 2018
  25. Cancer driver mutation prediction through Bayesian integration of multi-omic dataPLoS ONE · 2018
  26. Credentialing Individual Samples for Proteogenomic AnalysisMolecular & Cellular Proteomics · 2018
  27. Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell PhenotypeCell Reports · 2018
  28. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotypeSHILAP Revista de lepidopterología · 2018
  29. Survival Outcomes by TP53 Mutation Status in Metastatic Breast CancerJCO Precision Oncology · 2018
  30. Predicting high-risk endometrioid carcinomas using proteinsOncotarget · 2018
  31. Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanomaEMBO Molecular Medicine · 2018
  32. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancersNature Communications · 2018
  33. Machine Learning Identifies Stemness Features Associated with Oncogenic DedifferentiationCell · 2018
  34. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsCell · 2018
  35. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor ContextCell Reports · 2018
  36. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient SamplesCell · 2018
  37. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of CancerCell · 2018
  38. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human CancersCell Reports · 2018
  39. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell CarcinomaCell Reports · 2018
  40. Pathogenic Germline Variants in 10,389 Adult CancersCell · 2018
  41. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome AtlasCell Reports · 2018
  42. Driver Fusions and Their Implications in the Development and Treatment of Human CancersCell Reports · 2018
  43. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer TypesCell Reports · 2018
  44. Genomic and Functional Approaches to Understanding Cancer AneuploidyCancer Cell · 2018
  45. Systematic Analysis of Splice-Site-Creating Mutations in CancerCell Reports · 2018
  46. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome AtlasCell Reports · 2018
  47. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in CancerCancer Cell · 2018
  48. Perspective on Oncogenic Processes at the End of the Beginning of Cancer GenomicsCell · 2018
  49. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer TypesCell Reports · 2018
  50. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant MelanomaClinical Cancer Research · 2018